Orchestrating the immune Response
TO DEFEAT CANCER
Engineering precision immunity
Elicio Therapeutics is re-engineering the body’s immune response to defeat cancer with potent lymph node targeted immunotherapies. Elicio’s Amphiphile platform combines expertise in materials science, immunology and immuno-oncology to develop novel immunotherapies, including cell therapy activators, immunomodulators, adjuvants and vaccines for an array of aggressive cancers.
Lymph nodes:
where the immune response is orchestrated
Elicio has demonstrated preclinically that Amphiphiles target and concentrate an array of different immunotherapies in the lymph nodes, resulting in unprecedented tumor-specific immune responses and durable cures in multiple aggressive tumor models. Elicio’s lead Amphiphile program for KRAS-driven cancers will enter initial patient studies in 2020.
NEXT-GENERATION IMMUNO-ONCOLOGY PLATFORM
Our programs
Elicio will begin multiple Phase 1/2 studies for ELI-002 in 2020. This program consists of an Amphiphile vaccine that has the potential to elicit powerful immune responses against KRAS, a mutation found in 90% of pancreatic cancers, and 40% of colorectal cancers.
Latest News
November 11, 2020 ||
Elicio Announces Additions to Board of Directors
Elicio Therapeutics, a next generation immunotherapy company, has named Daphne Karydas, Chief Financial Officer at Syndax Pharmaceuticals and Carol Ashe, Chief Business Officer at the New York Genome Center, to its board of directors. » Read more
November 10, 2020 ||
Elicio Therapeutics Announces Poster Presentation at 2020 Society for Immunotherapy of Cancer Annual Meeting
Lymph node-targeted AMP-vaccine enables tumor-directed mKRAS-specific immune responses with potent polyfunctional and cytolytic activity. » Read more
Orchestrating the immune system for precision immunity — Download this article to see how Elicio’s lymph node-targeting Amphiphile technology delivers potent T cell activation and boosts the effects of engineered cell therapies.
A Lymph Node Targeted Amphiphile Vaccine Induces Potent Cellular and Humoral Immunity to SARS-CoV-2 Download this presentation